Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.

Publication

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.

Journal Paper/Review - Sep 2, 2022

Shoamanesh Ashkan, Mundl Hardi, Smith Eric E, Masjuan Jaime, Milanov Ivan, Hirano Teruyuki, Agafina Alina, Campbell Bruce, Caso Valeria, Mas Jean-Louis, Dong Qiang, Turcani Peter, Christensen Hanne, Ferro Jose M, Veltkamp Roland, Mikulik Robert, De Marchis Gian Marco, Robinson Thompson G, Lemmens Robin, Stepien Adam, Greisenegger Stefan, Roine Risto, Csiba Laszlo, Khatri Pooja, Coutinho Jonathan, Lindgren Arne G, Demchuk Andrew M, Colorado Pablo, Kirsch Bodo, Neumann-Haefelin Christoph, Heenan Laura, Xu Lizhen, Connolly Stuart J, Hart Robert G, PACIFIC-Stroke Investigators

Citation

Shoamanesh A, Mundl H, Smith E, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas J, Dong Q, Turcani P, Christensen H, Ferro J, Veltkamp R, Mikulik R, De Marchis G, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren A, Demchuk A, Colorado P, Kirsch B, Neumann-Haefelin C, Heenan L, Xu L, Connolly S, Hart R, PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400:997-1007.

Type

Journal Paper/Review (English)

Journal

Lancet 2022; 400

Publication Date

Sep 2, 2022

Issn Electronic

1474-547X

Pages

997-1007

Brief description/objective

Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown.